Patients with SLE are often young females of childbearing age and a pregnancy wish in this patient group is common. However, SLE patients are at high risk for adverse pregnancy outcomes that require adequate guidance. It is widely acknowledged that pre-pregnancy counselling is the pivotal first step in the management of SLE patients with a wish to become pregnant. Next, management of these patients is usually multidisciplinary and often requires specific expertise from the different physicians involved. Very recently a EULAR recommendation was published emphasizing the need for adequate preconception counselling and risk stratification. Therefore the present review specifically addresses the issue of pre-pregnancy counselling for SLE patients with an evidence-based approach. The review summarizes data retrieved from recently published, high-quality cohort studies that have contributed to a better understanding and estimation of pregnancy-related risks for SLE patients. The present review categorizes risks from a patient-oriented point of view, that is, the influence of pregnancy on SLE, of SLE on pregnancy, of SLE on the foetus/neonate and of SLE-related medication. Lastly, pre-pregnancy counselling of SLE patients with additional secondary APS is reviewed. Collectively these data can guide clinicians to formulate appropriate preventive strategies and patient-tailored monitoring plans during pre-pregnancy counselling of SLE patients.
Introduction
SLE is a systemic autoimmune disease that is predominantly diagnosed in young females and potentially affects any organ system [1] . APS is an autoimmune disease characterized by arterial or venous thrombosis, complications of pregnancy (e.g. miscarriages, severe pre-eclampsia, intrauterine foetal death and placental insufficiency) and the presence of autoantibodies against anti-phospholipids (i.e. against cardiolipin or b 2 -glycoproteins) or lupus anticoagulants. SLE has a remarkably high co-incidence with aPL, which is estimated at 3040% [2] , resulting in 1620% of SLE patients diagnosed with secondary APS [3] . SLE and secondary APS both have a peak incidence in young women at their reproductive age [mean 34 years (S.D. 13)] [2] . Therefore, in clinical practice, the desire to have children is very often a subject during consultation.
It is well known that SLE, with or without secondary APS, is associated with a higher rate of adverse pregnancy outcomes, including pregnancy-induced hypertension, pre-eclampsia, pre-term birth, intrauterine growth restriction (IUGR), foetal death, neonatal death small-forgestational-age neonates and increased maternal mortality [4] . Therefore a recent EULAR task force has developed recommendations for the management of SLE patients with a pregnancy wish, including the need for pre-pregnancy counselling and risk stratification [5] . As such, SLE patients who wish to become pregnant require a multidisciplinary team of physicians and caregivers who have expertise in handling diagnostic and therapeutic dilemmas before, during and after pregnancy and in counselling the future parents before conception about these dilemmas. Although the clinical challenges are evident, the low prevalence of SLE has hampered well-designed studies for many years. Clinicians have depended upon published experiences of small, mostly single-centre case series, cohorts and expert opinions [68] . However, in recent years our knowledge of pregnancies in SLE patients has increased due to the publication of several high-quality studies in large cohorts of pregnant SLE patients. Therefore this review aims to guide pre-pregnancy counselling of young women with SLE, including the effect of pregnancy on the course of the disease, the effect of the disease on pregnancy outcome, the influence of the disease on the foetus and neonate, inheritability and the effect of medication.
We present an overview of the recent literature including data on pregnancy outcomes from 24 SLE cohorts that resulted from a structured literature search (see supplementary Fig. S1 , available at Rheumatology Online, for details). While many of the published studies were retrospective, uncontrolled cohort studies, we identified enhanced quality of data from one prospective cohort study, two large casecontrol studies and one meta-analysis. Briefly, [4, 9-11]: Smyth et al. performed a metaanalysis of data from all published studies until 2009 investigating pregnancy outcome in SLE patients, including 37 studies covering 1842 SLE patients and 2751 pregnancies [11] . From all studied patients, 54% had a history of nephritis, 27% had signs of active nephritis and 34% had secondary APS. Clowse et al. reported data from a nationwide American registry of pregnancies comparing 13 555 SLE pregnancies with 16.7 million non-SLE pregnancies [4] . Arkema et al. published data from a nationwide Swedish registry comparing 551 SLE pregnancies with 12 847 non-SLE pregnancies [9] . Both studies demonstrated the important advantage of large registries capable of reporting pregnancy outcome in a relatively rare SLE population compared with non-SLE controls. However, an inherent drawback to registry studies is the lack of detailed patient characteristics and outcomes. Lastly, the first prospective inception cohort by Buyon et al.
[10] reported on the outcome of 385 SLE pregnancies from the Predictors of pRegnancy Outcome: bioMarkers In antiphospholipid antibody Syndrome and Systemic lupus Erythematosus (PROMISSE) study. Importantly, the PROMISSE cohort encompassed pre-pregnancycounselled SLE patients with confirmed low or no disease activity (as measured by an SLE disease activity index adapted to pregnant patients, physician's global assessment of disease activity on a visual analogue scale and proteinuria). Relevant data items on pregnancy outcomes in SLE patients from these four high-quality studies are summarized in Table 1 . We also summarized the most commonly reported and clinically relevant data from 20 retrospective, uncontrolled cohorts within a certain referral area (i.e. region of a country) ( Table 2) . Of interest, data from the large, high-quality studies strongly resembled overall prevalence data from the heterogeneous uncontrolled cohorts, as further discussed below.
Influence of pregnancy on SLE
An important consideration for physicians and women with SLE is the risk of an SLE flare. As can be deduced from Table 1 , in the meta-analysis, 26% of SLE patients experienced a flare of disease [11] , which was in accordance with a 24% incidence in the PROMISSE study [10] . In recent retrospective cohorts, SLE flares were reported in 34% of pregnancies (Table 2) . Importantly, from the prospective PROMISSE study, a distinction between mild and severe flares could be made: 80% of all flares were minor [i.e. in 20% (1/5) of all participating SLE patients] and generally manageable with (an increase of) steroids. Twenty percent of flares were severe, including nephritis, pleuritis, arthritis, thrombocytopenia, cerebritis, myositis and/or pericarditis [i.e. seen in 5% (1/25) of patients overall]. The consequences of these severe flares were largely determined by the gestational time: from the total of 92 (minor plus major) flares, 38 (41%) flares occurred beyond 36 weeks of pregnancy and 55 flares (59%) between 24 and 36 weeks of pregnancy. These flares led to preterm induced labour between 24 and 36 weeks in only two cases.
It is important to note that many of the reported pregnancy outcomes are derived from a population of SLE patients that had quiescent disease for at least 6 months, as recommended by international recommendations [6, 12] . The notion that disease activity at the start of pregnancy has a significant influence on pregnancy outcome was comprehensively studied by Petri et al. [13] : SLE patients with high disease activity in the first trimester had a significantly lower chance of a live birth (57 vs 84%) or full-term birth (21 vs 50%) and a significantly higher risk of miscarriage (29 vs 9%). High disease activity in the second and third trimester was associated with a significantly lower chance of full-term birth (28 vs 63%), higher risk of extreme preterm birth 428 weeks (18 vs 5%) and higher perinatal mortality (15 vs 4%). In retrospect, those patients who had active disease within 6 months prior to pregnancy were at the highest risk (58%) of a disease flare during pregnancy. Active disease within 6 months prior to pregnancy being associated with an SLE flare during pregnancy was also found in the large Toronto lupus registry [14] . In contrast, a disease flare during pregnancy was observed in only 8% of patients who had >6 months quiescent disease prior to pregnancy. Additionally, it was also shown that a history of LN increased the risk of an SLE flare during pregnancy by 3-fold [14] . Thus there is consensus that the risk of disease flare is associated with disease activity at conception and that one should strive for a 6 month pre-conceptional period of low to no disease activity. Whether this period can be shortened, for example, to 4 months, is still a matter of debate [15] Deduced from historical data, the general opinion was that patients with chronic kidney disease (CKD) are at increased risk for end-stage renal disease (ESRD) during or shortly after pregnancy [16] . However, recently a comprehensive meta-analysis nullified this notion. Comparing retrospectively 1514 pregnancies in CKD patients with approximately half a million pregnancies in non-CKD patients, no differences were found in the risk for doubling of serum creatinine or ESRD [17] . Also, risks were comparable between CKD stages 1, 2 and 3. The finding of previous studies that the risk for ESRD is highest for patients with CKD stages 45 who become pregnant [18] should be interpreted with caution and might reflect their natural course of progression and may be unrelated to pregnancy. With respect to possible deterioration of kidney function in SLE patients with (previous) renal involvement, Smyth et al.
[11] reported 2 patients (<1%) requiring dialysis of a total of 1842 patients included in the meta-analysis. Still, because kidney function was only moderately affected in most patients reported, subtle deteriorations and subclinical podocyte loss could not be accounted for in these studies [19, 20] .
Taken together for pre-pregnancy counselling, the influence of pregnancy on SLE disease can be assessed if a thorough assessment of disease activity prior to pregnancy has taken place. SLE patients with no or low disease activity have a risk of flaring of approximately one in four during pregnancy. The majority of these flares are minor and are likely treatable with non-immunosuppressive drugs or an increase in steroids. There is a chance of 1 in 25 to experience a severe disease flare during pregnancy, which rarely leads to the need for preterm induced labour. To date, the literature supports a period of quiescent disease of (at least) 6 months prior to pregnancy, because of the significant reduction of pregnancy-related complications. Lastly, patients with CKD and an estimated glomerular filtration rate of 545 ml/ min should be reassured that the risk for ESRD is probably not increased and is comparable to that of healthy women.
Influence of SLE on pregnancy
Maternal complications (Pre-)Eclampsia is a dynamic, progressive hypertensive disorder of pregnant women that is accompanied by symptoms of systemic thrombotic microangiopathy, such as renal insufficiency, elevated liver enzymes, neurological symptoms, signs of haemolysis and thrombocytopenia [21, 22] . Pre-eclampsia is therefore by definition a progressive disorder that may precede true eclampsia, which is associated with high morbidity and mortality [23] . Distinguishing (pre-)eclampsia from pre-existing kidney disease is sometimes difficult. Termination of pregnancy and removal of the placenta is the only effective treatment. The risk for pre-eclampsia in SLE patients was retrospectively reported by Smyth et al.
[11] at 8%; however, in prospective casecontrol and cohort studies the risk was 1623%, resulting in a 3-fold increased risk for SLE patients compared with healthy women. Likewise, a reported incidence of 15% in retrospective cohort studies has been observed (Tables 1 and 2 ). Accordingly, SLE is one of the consistent high-risk predictors of preeclampsia together with previous pre-eclampsia, APS, diabetes, chronic hypertension, renal disease and other autoimmune diseases [24] . A meta-analysis demonstrated a modest but significant effect of aspirin use to prevent pre-eclampsia in high-risk women [25] . Aspirin use also led to reductions in IUGR and preterm birth without an increase of perinatal or maternal harm. Therefore, although specific studies on aspirin in SLE patients are lacking, SLE patients can be advised to use low-dose aspirin throughout the pregnancy up to the 36th gestational week. It is then usually stopped to prevent prostaglandin-mediated premature closing of the ductus arteriosus [26] and to reduce the risk of bleeding complications during delivery.
SLE mothers are at considerably increased risk of maternal complications compared with healthy women, as illustrated in the study of Clowse et al. [4] . They reported an 18-fold higher risk for maternal mortality, 10-fold higher risk for major thrombosis (i.e. cerebrovascular accidents, pulmonary embolism or deep venous thrombosis) and 4-fold higher risk for infections. These maternal complications might be explained by an increased disease burden, the chronic use of immunosuppression rendering SLE patients susceptible to infection and the increased procoagulant state due to pregnancy, as well as the underlying presence of SLE (with or without the presence of aPL).
Foetal complications
It is well known that SLE can have a negative impact on foetal pregnancy outcome. Placental dysfunction due to shallow invasion of the syncytiotrophoblast originates very early in pregnancy, in the first trimester [27] . SLE patients are therefore at increased risk of placental vasculopathy leading to decreased feto-placental circulation and increased risk of pre-eclampsia. In the group of SLE patients, not further specified for the presence of secondary APS, Smyth et al.
[11] observed spontaneous miscarriages in 16% of pregnancies, which was similar to the reported 19% in uncontrolled cohort studies (Tables 1  and 2 ). Additionally, Smyth et al. found an overall rate of 23% unsuccessful pregnancies, 6% induced abortions and 13% IUGR. Reciprocally, 58% of SLE pregnancies had a good outcome, i.e. a live birth of a normally grown neonate. The PROMISSE study by Buyon et al.
[10] confirmed the latter prospectively: 61% of patients conceived without an adverse pregnancy outcome.
Data from Clowse et al. [4] showed that the risks for SLE patients compared with non-SLE pregnancies in more detail: SLE patients have a 3-fold higher risk for pre-eclampsia, 2.5-fold higher risk for preterm birth and 3-fold higher risk for IUGR. Importantly, the prevalence of IUGR was 923% in the pivotal studies [4, 10, 11] as well as in uncontrolled studies compared with 48% in the non-SLE population [9] (Tables 1 and 2 ).
Foetal or neonatal mortality is increased in pregnant SLE patients: Smyth et al.
[11] reported 3% foetal death and 4% neonatal death, the PROMISSE study observed 5 and 1%, respectively, and we calculated a reported 7% incidence of foetal or neonatal death combined in retrospective cohorts. These rates are higher than those seen in the general pregnant population (foetal death rate of 0.62.8%; USA and Europe 0.6%, Africa 2.8%) [28, 29] . More detail from the PROMISSE study showed that foetal death occurred before 24 weeks in 3%, between 24 and 36 weeks in 1% and after 36 weeks in 1%.
In conclusion, IUGR complicates up to one in four SLE pregnancies. SLE patients are at increased risk for foetal intrauterine death, mainly before foetal viability (<24 weeks of gestation) is achieved. So, during pre-pregnancy counselling, the influence of SLE on the foetus and/or neonate should be addressed from several angles: studies have shown that 1 in 15 pregnancies results in foetal or neonatal death, with most deaths occurring before the foetus is viable (i.e. before 24 weeks).
Taken together for pre-pregnancy counselling, the influence of SLE on pregnancy should not be underestimated. Although an estimated 60% of pregnancies will have a normal pregnancy outcome, one of five patients will have pre-eclampsia and 2030% of mothers will deliver prematurely. Importantly, SLE patients are at high risk for maternal complications, notably infections and thrombosis, although the prevalence is low.
Influence of SLE on the foetus/neonate
In SLE pregnancies, neonates are at increased risk of developing specific, clinical manifestations of neonatal lupus erythematosus (NLE), which is found to associate with maternal autoantibodies crossing the placenta. NLE is a disease of the developing foetus and neonate that is associated with maternal anti-Ro and anti-La autoantibodies. In the PROMISSE study, 42% were positive for anti-dsDNA, 41% for anti-SSa/Ro and 16% for anti-SSb/La autoantibodies [10] . The clinical syndrome consists of cutaneous manifestations, abnormalities of liver function (mostly cholestatic), hematologic abnormalities (anaemia, neutropenia and thrombocytopenia) and cardiac abnormalities (most commonly congenital heart block) [30] . The incidence rate of NLE is estimated at 510%. The most studied manifestation is cardiac neonatal lupus, and particularly congenital heart block (12%), due to its severity, necessity for intervention and potentially devastating prognosis. Except for congenital heart block, manifestations of neonatal lupus will disappear spontaneously after 36 months (speculatively related to the half-life of autoantibodies). Congenital heart block is characterized by foetal bradycardia and an atrioventricular block that develops during weeks 1824 of pregnancy, coinciding with the time that immunoglobulins can cross the placenta. Congenital heart block is associated with a perinatal mortality of 1520%, and most of the surviving children require permanent pacemaker implantation at an early age. Nevertheless, children surviving their first year of life have a good prognosis [3135] . A recent population study observed a prevalence of congenital heart block in 1/23 300 live births within the general population and 3.5/100 live births in the anti-SSapositive population [36] , suggesting (at the least) a 100-to 300-fold increased risk. Recurrent congenital heart block is seen in 17% of pregnancies and retrospective data from uncontrolled studies suggest a reduced incidence of congenital heart block in a previously affected mother when using HCQ during pregnancy [37] .
Lastly, a common question from SLE patients is whether the disease is inherited by future children. Genome-wide association studies have identified 30 genes accounting for 10% of the heritability of SLE. The rates of concordance are 2456% in monozygotic twins and 14% in dizygotic twins, with an heritability index estimated at 66% [38, 39] . A Danish population study showed a 14-fold increased risk of SLE in offspring from parents with SLE [40] . However, since the incidence of SLE in the general population is very low, the absolute risk for an SLE patient to conceive a child with SLE is negligible and patients can therefore be reassured on this matter during pre-pregnancy counselling.
In conclusion, SLE-related autoantibodies can cross the placenta and induce NLE in the foetus or neonate. Except for congenital heart block, manifestations of neonatal lupus will disappear spontaneously after 36 months. The most severe manifestation is congenital heart block, which is predominantly found in SLE mothers who have circulating anti-SSa/SSb autoantibodies. Although uncommon (13%), congenital heart block is associated with severe comorbidity and the need for pacemaker implantation. Whereas there is no therapeutic intervention available, prevention of recurrence in siblings was reported in patients taking HCQ. Early detection through weekly foetal heart rate monitoring between 18 and 24 weeks of gestation in anti-SSa/SSb-positive mothers is recommended.
Influence of SLE-related medication
One of the most essential parts of pre-pregnancy counselling in SLE patients is establishing the appropriate medication use. Commonly used therapies in SLE are analgesics, immunosuppressive medication, antihypertensives and anticoagulation medication. Many of these compounds are not compatible with pregnancy because of the associated risk of embryopathies, miscarriage or negative impacts on second and third trimester development. However, in SLE, an important starting point is that (presumed) toxicity of certain therapies should not automatically lead to discontinuation of this treatment, but rather should be balanced against the benefit of lowering the risk for disease flares and associated pregnancy complications. Current guidelines provide support for which treatment is recommended to continue and which not [12] . In addition, very recently the British Society of Rheumatology published their National Institute for Health and Care Excellenceaccredited guideline on prescription of drugs during pregnancy and breastfeeding for patients with rheumatic diseases [5, 41, 42] . Furthermore, the EULAR has published a statement on medication use in pregnancy [43] . In Table 3 we have summarized specific medications for SLE patients that are considered safe according to these guidelines.
When counselling SLE patients on medication use before and during pregnancy, one needs to be aware that there is little evidence to support a distinct treatment preference balancing safety and efficacy for pregnant SLE patients. An important principle in treatment choices during pregnancy is to strive for a certain level of uniformity between caregivers. With this perspective, defining a (local) standardized treatment protocol based on the restricted use of well-known and commonly used medications agreed upon by the relevant disciplines can be advantageous for three reasons: (i) there is a preference to establish expertise concerning the clinical effects, treatment interactions and safety profile of a small group of commonly used medications for SLE patients rather than the incidental usage of any treatment; (ii) the transfer of care for pregnant SLE patients is facilitated by standardization of treatment and a restricted, therapeutic armamentarium and (iii) operating in an area where very little evidence is available profits from standardization. The recently published guidelines on medication use during pregnancy for patients with a rheumatic disease could serve as valuable sources [41, 42] .
A growing issue involving immunosuppressive treatment in (pre-)pregnant SLE patients is the use of biologics. At this time, the only biologic approved for the treatment of SLE is belimumab, which is a monoclonal antibody directed against the B-lymphocyte stimulator cytokine (Blys). Data on the safety of belimumab in pregnancy are scarce, however, unintentional use in the first trimester seems not to be harmful [44] . With respect to rituximab (a mAb directed at the B-cell-specific membrane protein CD20), which is mostly used off-label in SLE patients, it is advised to preferably stop rituximab 6 months before conception [43] . Some advocate a more liberal approach, as the limited evidence available has not shown rituximab to be teratogenic, although it is associated with neonatal B-cell depletion when given in the second or third trimester. Unintentional rituximab exposure early in the first trimester is therefore unlikely to be harmful [41] . Taking these data together, it is reasonable to test for a pregnancy before the start of belimumab or off-label rituximab treatment, especially in those SLE patients in whom adequate conception prevention is not guaranteed. The use of rituximab during pregnancy should be avoided.
With respect to anticoagulants, special attention should be given to the new-generation direct oral anticoagulants (DOACs), i.e. apixaban, dabigatran and rivaroxaban [45, 46] . To date, there are a few observations of unintentional use of rivaroxaban in the first trimester of pregnancy [4749] . These studies are small and inconclusive with respect to safety but are, at most, illustrations of harm. Additionally, DOACs have been shown ex vivo to cross the placenta [50, 51] . Therefore, if an SLE patient is treated with a DOAC, the agent should be switched, preferably to heparin, when an active pregnancy wish is present.
With respect to antihypertensive or antiproteinuric treatment, several guidelines on hypertension treatment in pregnancy are helpful for taking treatment decisions [22, 52, 53] . Blood pressure (BP) treatment targets during pregnancy are generally liberal: patients with socalled uncomplicated pregnancy-induced hypertension with a systolic BP <160 mmHg or diastolic <110 mmHg not accompanied by proteinuria should not be treated [22] . However, SLE patients with previous renal involvement commonly suffer from pre-existing proteinuria even before conception. In this case, optimal pre-conceptual BP lowering is advised, aiming at a stable treatment regimen with proteinuria <0.5 g/24 h. During pregnancy, an increase in blood pressure and proteinuria should raise suspicion of pre-eclampsia or a lupus flare and requires evaluation accordingly. An overview of safe-to-use antihypertensive drugs is given in Table 3 . Importantly, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers are not considered safe during pregnancy [5358] . Information on medication use during breastfeeding is scarce. There is little information on drug concentration in human breast milk and whether it has any pharmacological effects in breastfed babies. Labetalol, nifedipine, enalapril, captopril and metoprolol are considered safe for use during lactation [59] . There are insufficient data on the safety of other ACE inhibitors, angiotensin receptor blockers or calcium antagonists [59] . SLE patients should be well informed about the need to continue effective treatment in the postnatal period. It is recommended to review long-term antihypertensive treatment 2 weeks after the birth. If hypertension or proteinuria is not controlled, patients should be advised to stop breastfeeding in order to receive adequate treatment and optimal further diagnostics to evaluate the underlying cause.
Lastly, well-designed studies addressing pregnancy outcomes in male SLE patients exposed to DMARDs during conception are lacking. With regard to paternal use of methotrexate, a recent prospective cohort study observed no harmful effect to pregnancy outcome, which was further corroborated in the recent BSR guideline that found no evidence of harm [61, 62] . Therefore, paternal use of low-dose MTX during conception does not need to be changed. Paternal use of other DMARDs such as thiopurines, SSZ and anti-TNF therapy has been studied in a variety of inflammatory diseases, including RA, SpA and IBD. These studies did not show differences in pregnancy or birth outcomes compared with patients without DMARD use or healthy controls [6264] .
Collectively, for pre-pregnancy counselling, medication review is mandatory. A locally standardized protocol is recommended even though (pre-)conceptual maintenance treatment should be personalized according to disease manifestations, disease history and disease refractoriness for each SLE patient. Importantly, when the immunosuppressive regimen is changed it is recommended to evaluate its efficacy for 46 months to ascertain stable disease control before conception.
Influence of secondary APS on SLE pregnancy
In 1620% of SLE patients a secondary APS is diagnosed [3]. The PROMISSE study observed a 3-fold increase in adverse pregnancy outcomes in SLE patients with secondary APS (44%) compared with SLE patients without secondary APS (15%). Of note, adverse pregnancy outcomes were observed in 3% of healthy control subjects [10] . These data emphasize the importance of determining whether secondary APS is present in an SLE patient. Guidelines for diagnosing APS have adopted the Sydney criteria encompassing the following: a vascular thrombotic event or a history of pregnancy morbidity together with a confirmed positive test (12 weeks apart) of any of the aPLs (i.e. lupus anticoagulant, anticardiolipin or anti-b 2 -glycoprotein) [65, 66] . A vascular thrombotic event includes any (history of) arterial, venous or small-vessel (i.e. superficial) thrombosis in any tissue or organ. Pregnancy-related morbidity was defined as one or more unexplained foetal death beyond the 10th week of gestation, one or more premature birth before the 34th week of gestation due to placental insufficiency, one or more episode of eclampsia or severe pre-eclampsia, one or more episode of placental insufficiency or three or more unexplained consecutive spontaneous abortions before the 10th week of gestation.
SLE patients fulfilling the criteria for APS should be treated with anticoagulant treatment from the moment a pregnancy is confirmed [3] . Of note, there is currently no evidence for pre-conceptual use of heparins or immunosuppressive therapy (e.g. IVIG, steroids). Clinical studies as to which anticoagulant treatment is most effective remain unsatisfactory for daily practice. Pivotal randomized trials have shown that unfractionated heparin combined with low-dose aspirin significantly reduced the incidence of pregnancy loss in women who had a history of recurrent losses [6769] . Confusingly enough, the [41] and EULAR statement [43] . b Based on NICE guideline for hypertension treatment [59] and ACOG guideline for hypertension in pregnancy [22] . Based on BSR guidelines for treatment in rheumatic diseases [41] . combination of low molecular weight heparin (LMWH; instead of unfractioned heparin) combined with low-dose aspirin did not result in a reduced rate of pregnancy loss compared with aspirin alone [67, 70, 71] . To better understand the published evidence, a recent network meta-analysis involving 19 trials encompassing 2391 patients with recurrent miscarriages and 543 APS patients was performed [72] . This study observed no significant beneficial effect of any antithrombotic treatment, illustrating the lack of evidence to support a single, one-size-fitsall treatment strategy for patients with recurrent miscarriages, with or without underlying APS. However, unfractionated heparin plus aspirin had the highest probability (75%) to be ranked as a superior treatment for APS patients with recurrent miscarriages. LMWH combined with aspirin had a probability of 66% to be ranked as a superior treatment.
In conclusion, we recommend in daily practice LMWH in combination with aspirin, because of proven safety and ease of use. It is prescribed both antenatally and until 6 weeks post-partum as thrombosis prophylaxis [73] . Generally, after one or more thrombotic events, many SLE patients with secondary APS will already be chronically treated with oral anticoagulants and will be switched to therapeutic dosages of LMWH as soon as they are pregnant. There is proven toxicity for the embryo from warfarin, especially in the first trimester, and therefore early and prompt switching to LMWH is indicated once a pregnancy test is positive [74] .
In SLE patients with persistently detectable aPL but without previous venous thromboembolism, no other risk factors or obstetric indications for close surveillance of LMWH is recommended. Besides low-dose aspirin, there is generally no anticoagulation started during pregnancy [75] . Still, post-partum thrombosis prophylaxis can be considered generally for the duration of 6 weeks [76] , due to the increased risk of thrombosis.
There is growing support for the use of HCQ during pregnancy, especially in SLE patients with APS. HCQ is commonly used in SLE patients to prevent flares of the disease, is thought to be safe during (pre-)pregnancy and lactation and may be beneficial for SLE pregnancy outcome. Recently a retrospective study investigating 118 SLE pregnancies was published showing fewer preterm births and less IUGR in women who used HCQ during pregnancy as compared with those who did not [77] . Earlier studies showed similar findings in patients with SLE or with APS alone [78, 79] . These data support that every SLE patient wishing to become pregnant should use HCQ irrespective of the presence of secondary APS.
In conclusion, for SLE patients with secondary APS, it is strongly advised to add LMWH to aspirin throughout pregnancy and in the post-partum period. HCQ is safe and should be continued in all SLE patients, particularly those with concurrent APS. SLE patients with aPLs without established APS have no indication for anticoagulant treatment during pregnancy but should be on prophylactic treatment post-partum.
Conclusion
We reviewed the different pivotal studies that have been published in recent years, which have added valuable knowledge on pregnancy outcomes in SLE patients to guide pre-pregnancy counselling. Thanks to the efforts of investigators to collect data on the rare but vulnerable population of young SLE women, we have moved away from guesstimating the pregnancy risks to finding solid ground to anticipate risks for the SLE mother and her unborn child. Taking into account all the data on increased risks for patients as well as the foetuses in SLE pregnancies and the complexity of medication management before and during pregnancy, it is clear that prepregnancy counselling for SLE patients demands a multidisciplinary approach [80] . Many of the maternal and foetal risks in SLE pregnancy can be anticipated and therefore multidisciplinary pre-pregnancy counselling should be regarded as a key for successful management of a pregnancy in patients with SLE and/or APS. In this way, multidisciplinary pre-pregnancy counselling will result in an integral, patient-tailored treatment plan for the pre-conception, pregnancy, delivery and postpartum periods. Ultimately this will enhance the clarity and perception of control for patients, partners as well as physicians to manage high-risk SLE pregnancies.
For future studies, the long-term outcome of SLE mothers and their children is an underdeveloped area. Studies have demonstrated an increased risk of cardiovascular disease and mortality in mothers with preeclampsia and recurrent miscarriages [81, 82] . Because SLE mothers have an increased risk of maternal complications, future investigations will need to elucidate whether SLE patients who have experienced pregnancy complications have poorer outcomes in the long-term compared with other SLE patients.
patterns of disease expression in a cohort of 1,000 
Lung involvement in polymyalgia rheumatica
A 72-year-old man presented with a 4-week history of coughing and pain in the shoulders and hips, with morning stiffness. Physical examination revealed a limited range of motion of the shoulder and hip joints owing to pain. The temporal arteries were neither tender nor pulseless. Serum ESR was high. A chest radiograph showed an infiltrate in the left upper lobe and nodular opacities in the right middle and lower lobes (Fig. 1A) . PET/CT demonstrated accumulation of fluorodeoxyglucose in the shoulder joints, lateral sides of the greater trochanters, the right ischial tuberosity and the lung lesions (Fig. 1BE) . Large vessels were not affected. Transbronchial lung biopsy identified organizing pneumonia. A diagnosis of organizing pneumonia associated with PMR was made. His symptoms and chest radiological abnormalities resolved after treatment with oral prednisolone. Interstitial lung diseases, which are histopathologically classified into usual interstitial pneumonia, non-specific interstitial pneumonia, organizing pneumonia with diffuse alveolar damage, and lymphocytic interstitial pneumonia, are encountered in patients with various CTDs [1] . Although lung involvement is very rare in PMR, temporal arteritis and GCA, organizing pneumonia can be a lung manifestation of PMR [2] .
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